MA53927A - Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel - Google Patents

Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Info

Publication number: MA53927A
Authority: MA; Morocco
Prior art keywords: salt; pharmaceutical composition; oral administration; aminopyrimidine derivative; aminopyrimidine
Prior art date: 2018-10-18

Application number

MA053927A

Other languages

English (en)

Other versions

MA53927B1 (fr

Inventor

Seongkyu Kim

Soo-Won Kim

Deokkyu Lee

Yoong-Sik Park

Jun-Mo Yang

Original Assignee

Yuhan Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-10-18

Filing date

2019-10-17

Publication date

2021-09-15

2019-10-17 Application filed by Yuhan Corp filed Critical Yuhan Corp

2021-09-15 Publication of MA53927A publication Critical patent/MA53927A/fr

2023-12-29 Publication of MA53927B1 publication Critical patent/MA53927B1/fr

Links

150000005005 aminopyrimidines Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)

MA53927A 2018-10-18 2019-10-17 Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel MA53927B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020180124171A KR20200043618A (ko)	2018-10-18	2018-10-18	아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
PCT/IB2019/058862 WO2020079637A1 (fr)	2018-10-18	2019-10-17	Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Publications (2)

Publication Number	Publication Date
MA53927A true MA53927A (fr)	2021-09-15
MA53927B1 MA53927B1 (fr)	2023-12-29

Family

ID=70282933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA53927A MA53927B1 (fr)	2018-10-18	2019-10-17	Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel

Country Status (31)

Country	Link
US (1)	US12318390B2 (fr)
EP (2)	EP3866767B1 (fr)
JP (2)	JP7369769B2 (fr)
KR (3)	KR20200043618A (fr)
CN (2)	CN113015521B (fr)
AR (1)	AR117655A1 (fr)
AU (2)	AU2019360446B2 (fr)
BR (1)	BR112021007061A2 (fr)
CA (1)	CA3116652A1 (fr)
DK (1)	DK3866767T3 (fr)
EA (1)	EA202191061A1 (fr)
ES (1)	ES2968966T3 (fr)
FI (1)	FI3866767T3 (fr)
HR (1)	HRP20231670T1 (fr)
HU (1)	HUE065389T2 (fr)
IL (1)	IL282163B2 (fr)
LT (1)	LT3866767T (fr)
MA (1)	MA53927B1 (fr)
MD (1)	MD3866767T2 (fr)
MX (2)	MX2021004457A (fr)
MY (1)	MY208983A (fr)
PE (1)	PE20211818A1 (fr)
PH (1)	PH12021550687A1 (fr)
PL (1)	PL3866767T3 (fr)
PT (1)	PT3866767T (fr)
RS (1)	RS65012B1 (fr)
SG (1)	SG11202103057RA (fr)
SI (1)	SI3866767T1 (fr)
SM (1)	SMT202300491T1 (fr)
TW (1)	TWI831848B (fr)
WO (1)	WO2020079637A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR111469A1 (es)	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MY208668A (en) *	2019-05-14	2025-05-23	Janssen Biotech Inc	Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en)	2019-05-14	2023-12-26	Yuhan Corporation	Therapies with 3rd generation EGFR tyrosine kinase inhibitors
BR112022015140A2 (pt)	2020-02-12	2022-10-11	Janssen Biotech Inc	Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
TWI923583B (zh) *	2020-04-14	2026-05-01	美商健生生物科技公司	包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
EP4349835A4 (fr)	2021-06-01	2025-06-25	Hangzhou Solipharma Co., Ltd.	Forme cristalline d'hydrate de méthanesulfonate de lazertinib, son procédé de préparation et son utilisation
CA3228195A1 (en)	2023-05-23	2025-06-30	Janssen Biotech, Inc.	Methods for treatment of non-small cell lung cancer (nsclc)
IL326946A (en)	2023-09-05	2026-05-01	Janssen Biotech Inc	Methods of treating non-small cell lung cancer
WO2025206726A1 (fr) *	2024-03-26	2025-10-02	(주)신테카바이오	Composition pharmaceutique pour la prévention ou le traitement de maladies liées à la dépression ou à l'anxiété, contenant du lazertinib ou un sel pharmaceutiquement acceptable de celui-ci
WO2026042017A1 (fr)	2024-08-19	2026-02-26	Janssen Biotech, Inc.	Amivantamab en association avec le lazertinib pour le traitement du cancer du poumon non à petites cellules (cpnpc)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200100172T2 (tr) *	1998-07-20	2001-05-21	Smithkline Beecham Corporation	Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar
DE10319450A1 (de)	2003-04-30	2004-11-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Formulierung des Telmisartan Natriumsalzes
DE602007011792D1 (de) *	2006-10-27	2011-02-17	Fmc Corp	Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen
ES2359377T3 (es) *	2006-10-27	2011-05-23	Fmc Corporation	Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
US11453646B2 (en) *	2011-07-27	2022-09-27	Cornell University	Methods for RNA detection and quantification
CA2848493A1 (fr)	2011-09-14	2013-03-21	Celgene Corporation	Formulations de {2-[(1s)-l-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonyl- ethyl]-3-oxo-2,3-dihydro-lh-isoindol-4- yl}amide d'acide cyclopropanecarboxylique
SG11201402609RA (en)	2011-11-29	2014-06-27	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis c virus
WO2014175986A2 (fr) *	2013-04-23	2014-10-30	RevOrtho LLC	Procédé et système de reconstruction de hanche modulaire
GB201400034D0 (en)	2014-01-02	2014-02-19	Astrazeneca Ab	Pharmaceutical Compositions comprising AZD9291
EP3929190B1 (fr) *	2014-10-13	2024-12-25	Yuhan Corporation	Composés et compositions de modulation des activités de kinase mutant egfr
EP3712134B1 (fr)	2014-12-16	2023-11-29	Signal Pharmaceuticals, LLC	Sels de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
CN104788427B (zh)	2015-02-05	2017-05-31	上海泓博智源医药股份有限公司	3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
CA2986522A1 (fr)	2015-05-22	2016-12-01	Novartis Ag	Compositions pharmaceutiques
WO2017061621A1 (fr)	2015-10-07	2017-04-13	協和発酵キリン株式会社	Composition pharmaceutique contenant un composé d'arylalkylamine
IL261998B2 (en) *	2016-04-07	2023-03-01	Chemocentryx Inc	Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
AR111469A1 (es) *	2017-04-21	2019-07-17	Yuhan Corp	Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
TWI923583B (zh) *	2020-04-14	2026-05-01	美商健生生物科技公司	包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物

2018
- 2018-10-18 KR KR1020180124171A patent/KR20200043618A/ko active Pending
2019
- 2019-10-17 PL PL19872427.0T patent/PL3866767T3/pl unknown
- 2019-10-17 EA EA202191061A patent/EA202191061A1/ru unknown
- 2019-10-17 RS RS20231252A patent/RS65012B1/sr unknown
- 2019-10-17 MY MYPI2021002062A patent/MY208983A/en unknown
- 2019-10-17 US US17/285,161 patent/US12318390B2/en active Active
- 2019-10-17 JP JP2021520564A patent/JP7369769B2/ja active Active
- 2019-10-17 EP EP19872427.0A patent/EP3866767B1/fr active Active
- 2019-10-17 IL IL282163A patent/IL282163B2/en unknown
- 2019-10-17 PE PE2021000495A patent/PE20211818A1/es unknown
- 2019-10-17 CA CA3116652A patent/CA3116652A1/fr active Pending
- 2019-10-17 SM SM20230491T patent/SMT202300491T1/it unknown
- 2019-10-17 MD MDE20210799T patent/MD3866767T2/ro unknown
- 2019-10-17 SG SG11202103057RA patent/SG11202103057RA/en unknown
- 2019-10-17 FI FIEP19872427.0T patent/FI3866767T3/fi active
- 2019-10-17 ES ES19872427T patent/ES2968966T3/es active Active
- 2019-10-17 DK DK19872427.0T patent/DK3866767T3/da active
- 2019-10-17 CN CN201980068641.1A patent/CN113015521B/zh active Active
- 2019-10-17 SI SI201930673T patent/SI3866767T1/sl unknown
- 2019-10-17 MX MX2021004457A patent/MX2021004457A/es unknown
- 2019-10-17 HU HUE19872427A patent/HUE065389T2/hu unknown
- 2019-10-17 MA MA53927A patent/MA53927B1/fr unknown
- 2019-10-17 CN CN202411659054.9A patent/CN119523922A/zh active Pending
- 2019-10-17 AU AU2019360446A patent/AU2019360446B2/en active Active
- 2019-10-17 KR KR1020217014600A patent/KR102760314B1/ko active Active
- 2019-10-17 KR KR1020257002203A patent/KR20250025475A/ko active Pending
- 2019-10-17 TW TW108137395A patent/TWI831848B/zh active
- 2019-10-17 WO PCT/IB2019/058862 patent/WO2020079637A1/fr not_active Ceased
- 2019-10-17 EP EP23211951.1A patent/EP4306113A3/fr active Pending
- 2019-10-17 PT PT198724270T patent/PT3866767T/pt unknown
- 2019-10-17 BR BR112021007061-3A patent/BR112021007061A2/pt unknown
- 2019-10-17 HR HRP20231670TT patent/HRP20231670T1/hr unknown
- 2019-10-17 LT LTEPPCT/IB2019/058862T patent/LT3866767T/lt unknown
- 2019-10-18 AR ARP190102972A patent/AR117655A1/es active IP Right Grant
2021
- 2021-03-25 PH PH12021550687A patent/PH12021550687A1/en unknown
- 2021-04-16 MX MX2023014946A patent/MX2023014946A/es unknown
2023
- 2023-10-16 JP JP2023177976A patent/JP2024016052A/ja not_active Withdrawn
2024
- 2024-09-02 AU AU2024216519A patent/AU2024216519B2/en active Active

Also Published As

Publication number	Publication date
EP3866767A1 (fr)	2021-08-25
CA3116652A1 (fr)	2020-04-23
MX2023014946A (es)	2024-02-20
KR20210061457A (ko)	2021-05-27
KR102760314B1 (ko)	2025-02-03
PE20211818A1 (es)	2021-09-14
DK3866767T3 (da)	2024-01-29
CN113015521B (zh)	2025-05-13
IL282163B1 (en)	2025-05-01
AU2019360446A1 (en)	2021-04-22
JP2024016052A (ja)	2024-02-06
BR112021007061A2 (pt)	2021-07-20
MA53927B1 (fr)	2023-12-29
HUE065389T2 (hu)	2024-05-28
ES2968966T3 (es)	2024-05-14
JP2022504943A (ja)	2022-01-13
EP3866767A4 (fr)	2022-07-20
RS65012B1 (sr)	2024-01-31
PL3866767T3 (pl)	2024-04-02
TWI831848B (zh)	2024-02-11
WO2020079637A1 (fr)	2020-04-23
US20210322428A1 (en)	2021-10-21
TW202034903A (zh)	2020-10-01
US12318390B2 (en)	2025-06-03
NZ774402A (en)	2024-08-30
WO2020079637A9 (fr)	2020-07-23
SI3866767T1 (sl)	2024-02-29
CN113015521A (zh)	2021-06-22
PT3866767T (pt)	2024-01-18
AU2024216519A1 (en)	2024-09-19
FI3866767T3 (fi)	2024-01-30
KR20200043618A (ko)	2020-04-28
EA202191061A1 (ru)	2021-07-09
KR20250025475A (ko)	2025-02-21
PH12021550687A1 (en)	2022-02-14
CN119523922A (zh)	2025-02-28
SG11202103057RA (en)	2021-05-28
HRP20231670T1 (hr)	2024-03-15
MY208983A (en)	2025-06-14
SMT202300491T1 (it)	2024-01-10
EP3866767B1 (fr)	2023-11-29
LT3866767T (lt)	2023-12-27
MD3866767T2 (ro)	2024-06-30
AU2024216519B2 (en)	2025-11-20
AR117655A1 (es)	2021-08-25
IL282163A (en)	2021-05-31
AU2019360446B2 (en)	2024-09-19
IL282163B2 (en)	2025-09-01
JP7369769B2 (ja)	2023-10-26
EP4306113A2 (fr)	2024-01-17
EP4306113A3 (fr)	2024-02-14
MX2021004457A (es)	2021-07-07

Publication	Publication Date	Title
EP3866767A4 (fr)	2022-07-20	Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
EP4087406A4 (fr)	2024-01-10	Compositions vésiculaires pour une administration par voie orale
MA50557A (fr)	2020-09-16	Pistons pour dispositifs d'administration de médicament
MA51617A (fr)	2020-11-25	Mécanisme d'administration de médicament
EP3549588A4 (fr)	2020-06-24	Composition pharmaceutique pour prévenir ou traiter le cancer du foie, comprenant un polymorphe cristallin d'hexaoxyde de tétra-arsenic
EP3616696A4 (fr)	2021-01-27	Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
EP3256149A4 (fr)	2019-08-14	Formulations pour administration orale d'agents actifs
EP3621656A4 (fr)	2021-01-27	Formulation pour l'administration d'un médicament pour les yeux
EP4674481A3 (fr)	2026-03-04	Inhibiteurs de cd73
MA49253A (fr)	2020-04-15	Compositions solides pour administration orale
EP3498264A4 (fr)	2020-03-11	Préparation pharmaceutique pour administration orale à vitesse de dissolution contrôlée, la préparation comprenant des pastilles à libération prolongée contenant du chlorhydrate de tamsulosine
MA56102A (fr)	2022-04-13	Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
EP3500291A4 (fr)	2020-03-11	Formulations pour l'administration par voie orale d'agents actifs
EP3313379A4 (fr)	2019-04-10	Forme posologique pharmaceutique par voie orale pour l'administration d'un peptide et/ou d'une protéine
MA52154A (fr)	2020-06-10	Composition pharmaceutique pour l'anémie
EP3509573A4 (fr)	2020-04-29	Compositions pharmaceutiques pour l'administration d'un peptide
EP2987491A4 (fr)	2016-12-28	Composition pharmaceutique administrable par voie orale pour la prévention ou le traitement de la kératoconjonctivite sèche, comprenant du rebamipide ou un promédicament correspondant
EP3318259A4 (fr)	2019-02-27	Composition pharmaceutique stable pour administration par voie orale
EP4046498A4 (fr)	2022-11-16	Composition pour inhiber la production de hmf comprenant de l'allulose disaccharide
EP4015001A4 (fr)	2023-06-14	Composition pharmaceutique orale
EP3801539A4 (fr)	2022-02-23	Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
EP3829576A4 (fr)	2022-05-11	Composition pharmaceutique comprenant de l'eltrombopag olamine
EP3790543A4 (fr)	2022-03-30	Compositions et formes posologiques pour administration orale
EP3843785A4 (fr)	2022-06-01	Compositions comprenant des stimulants de la perméation pour l'administration de médicaments
EP3326628A4 (fr)	2019-03-20	Composition pharmaceutique pour l'administration par voie orale comprenant un taxane à haute concentration